Literature DB >> 25385620

Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes.

Kazuo Takayama1, Yuta Morisaki2, Shuichi Kuno2, Yasuhito Nagamoto3, Kazuo Harada4, Norihisa Furukawa2, Manami Ohtaka5, Ken Nishimura6, Kazuo Imagawa7, Fuminori Sakurai8, Masashi Tachibana2, Ryo Sumazaki9, Emiko Noguchi10, Mahito Nakanishi5, Kazumasa Hirata4, Kenji Kawabata11, Hiroyuki Mizuguchi12.   

Abstract

Interindividual differences in hepatic metabolism, which are mainly due to genetic polymorphism in its gene, have a large influence on individual drug efficacy and adverse reaction. Hepatocyte-like cells (HLCs) differentiated from human induced pluripotent stem (iPS) cells have the potential to predict interindividual differences in drug metabolism capacity and drug response. However, it remains uncertain whether human iPSC-derived HLCs can reproduce the interindividual difference in hepatic metabolism and drug response. We found that cytochrome P450 (CYP) metabolism capacity and drug responsiveness of the primary human hepatocytes (PHH)-iPS-HLCs were highly correlated with those of PHHs, suggesting that the PHH-iPS-HLCs retained donor-specific CYP metabolism capacity and drug responsiveness. We also demonstrated that the interindividual differences, which are due to the diversity of individual SNPs in the CYP gene, could also be reproduced in PHH-iPS-HLCs. We succeeded in establishing, to our knowledge, the first PHH-iPS-HLC panel that reflects the interindividual differences of hepatic drug-metabolizing capacity and drug responsiveness.

Entities:  

Keywords:  CYP2D6; SNP; hepatocyte; human iPS cells; personalized drug therapy

Mesh:

Substances:

Year:  2014        PMID: 25385620      PMCID: PMC4250156          DOI: 10.1073/pnas.1413481111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

Review 1.  Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.

Authors:  M Ingelman-Sundberg
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

2.  Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

Authors:  E Spina; C Gitto; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Authors:  Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart
Journal:  Clin Pharmacol Ther       Date:  2006-07       Impact factor: 6.875

4.  Mechanisms of benzarone and benzbromarone-induced hepatic toxicity.

Authors:  Priska Kaufmann; Michael Török; Anya Hänni; Paul Roberts; Rodolfo Gasser; Stephan Krähenbühl
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

5.  Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

Authors:  O M Bakke; M Manocchia; F de Abajo; K I Kaitin; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

Review 6.  Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes.

Authors:  M Ingelman-Sundberg
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

7.  A chemical platform for improved induction of human iPSCs.

Authors:  Tongxiang Lin; Rajesh Ambasudhan; Xu Yuan; Wenlin Li; Simon Hilcove; Ramzey Abujarour; Xiangyi Lin; Heung Sik Hahm; Ergeng Hao; Alberto Hayek; Sheng Ding
Journal:  Nat Methods       Date:  2009-10-18       Impact factor: 28.547

8.  Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.

Authors:  Matthew G McDonald; Allan E Rettie
Journal:  Chem Res Toxicol       Date:  2007-11-20       Impact factor: 3.739

Review 9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Long-term self-renewal of human ES/iPS-derived hepatoblast-like cells on human laminin 111-coated dishes.

Authors:  Kazuo Takayama; Yasuhito Nagamoto; Natsumi Mimura; Katsuhisa Tashiro; Fuminori Sakurai; Masashi Tachibana; Takao Hayakawa; Kenji Kawabata; Hiroyuki Mizuguchi
Journal:  Stem Cell Reports       Date:  2013-10-03       Impact factor: 7.765

View more
  64 in total

1.  Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema.

Authors:  Didde Haslund; Laura Barrett Ryø; Sara Seidelin Majidi; Iben Rose; Kristian Alsbjerg Skipper; Tue Fryland; Anja Bille Bohn; Claus Koch; Martin K Thomsen; Yaseelan Palarasah; Thomas J Corydon; Anette Bygum; Lene N Nejsum; Jacob Giehm Mikkelsen
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

2.  Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells.

Authors:  Akihiro Asai; Eitaro Aihara; Carey Watson; Reena Mourya; Tatsuki Mizuochi; Pranavkumar Shivakumar; Kieran Phelan; Christopher Mayhew; Michael Helmrath; Takanori Takebe; James Wells; Jorge A Bezerra
Journal:  Development       Date:  2017-03-15       Impact factor: 6.868

Review 3.  Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-09-05       Impact factor: 5.187

Review 4.  Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions.

Authors:  Shyam Sundhar Bale; Laura Moore; Martin Yarmush; Rohit Jindal
Journal:  Tissue Eng Part B Rev       Date:  2016-06-01       Impact factor: 6.389

Review 5.  Cell sources for in vitro human liver cell culture models.

Authors:  Katrin Zeilinger; Nora Freyer; Georg Damm; Daniel Seehofer; Fanny Knöspel
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-05

6.  Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells.

Authors:  Derek T Peters; Christopher A Henderson; Curtis R Warren; Max Friesen; Fang Xia; Caroline E Becker; Kiran Musunuru; Chad A Cowan
Journal:  Development       Date:  2016-05-01       Impact factor: 6.868

7.  Hepatocyte Nuclear Factor 4 Alpha Promotes Definitive Endoderm Differentiation from Human Induced Pluripotent Stem Cells.

Authors:  Morifumi Hanawa; Kazuo Takayama; Fuminori Sakurai; Masashi Tachibana; Hiroyuki Mizuguchi
Journal:  Stem Cell Rev Rep       Date:  2017-08       Impact factor: 5.739

Review 8.  Modeling rare diseases with induced pluripotent stem cell technology.

Authors:  Ruthellen H Anderson; Kevin R Francis
Journal:  Mol Cell Probes       Date:  2018-01-05       Impact factor: 2.365

Review 9.  Stem cell-derived liver cells for drug testing and disease modeling.

Authors:  Matthew D Davidson; Brenton R Ware; Salman R Khetani
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

10.  One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells.

Authors:  Annika Asplund; Arvind Pradip; Mariska van Giezen; Anders Aspegren; Helena Choukair; Marie Rehnström; Susanna Jacobsson; Nidal Ghosheh; Dorra El Hajjam; Sandra Holmgren; Susanna Larsson; Jörg Benecke; Mariela Butron; Annelie Wigander; Karin Noaksson; Peter Sartipy; Petter Björquist; Josefina Edsbagge; Barbara Küppers-Munther
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.